- Home
- SGMT
SGMT
Sagimet Biosciences Inc. Series A
as 12-18-2024 12:42pm EST
Stocks
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | SAN MATEO |
| Market Cap: | N/A | IPO Year: | 2023 |
| Target Price: | $23.00 | AVG Volume (30 days): | 723.1K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.39 - $20.71 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Sagimet Biosciences Inc. Series A News
SGMT Breaking Stock News: Dive into SGMT Ticker-Specific Updates for Smart Investing
TipRanks
3 days ago
Oppenheimer Predicts Up to ~580% Jump for These 2 ‘Strong Buy’ Stocks
GlobeNewswire
22 days ago
Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
GlobeNewswire
a month ago
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
Simply Wall St.
a month ago
Institutional investors in Sagimet Biosciences Inc. (NASDAQ:SGMT) see US$36m decrease in market cap last week, although long-term gains have benefitted them.
GlobeNewswire
a month ago
Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire
a month ago
Sagimet Biosciences to Participate in the UBS Global Healthcare Conference
GlobeNewswire
2 months ago
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024
GlobeNewswire
2 months ago
Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024
Compare SGMT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SGMT Sagimet Biosciences Inc. Series A - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.